• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
5.71% $1.49

MESOBLAST LIMITED - Announcements

Market Cap $1.113B  ! watchlist Created with Sketch. Add to my watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MSB Ceasing to be a substantial holder-MSB.AX 12/05/16
MSB Change in substantial holding-MSB.AX 12/05/16
MSB Mesoblast Provides Q3 Financial Results and Corporate Update-MSB.AX PRICE SENSITIVE10/05/16
MSB Third Quarter Results Presentation-MSB.AX 10/05/16
MSB Third Quarter Financial Results On Form 6-K-MSB.AX PRICE SENSITIVE10/05/16
MSB Change in substantial holding-J.P.Morgan-MSB.AX 09/05/16
MSB Change in substantial holding-MSB.AX 09/05/16
MSB Appendix 4C - quarterly-MSB.AX PRICE SENSITIVE28/04/16
MSB Appendix 3B and Prospectus for Issue of Employee Options-MSB.AX 28/04/16
MSB Release of Shares from Voluntary Escrow-MSB.AX 19/04/16
MSB Mesoblast Cells Show Disease Modifying Effects on Knee OAPRICE SENSITIVE01/04/16
MSB Key US Patent Granted For Treatment Of Rheumatoid ArthritisPRICE SENSITIVE24/03/16
MSB Mesoblast Technology Shows Potential In Type 1 Diabetes17/03/16
MSB Appendix 3B26/02/16
MSB GVHD Product Launched In JapanPRICE SENSITIVE24/02/16
MSB Increased Survival Using MSB Cells In Children With aGVHDPRICE SENSITIVE22/02/16
MSB Mesoblast Reports on First Half and Second Quarter Results17/02/16
MSB Half Year Results Presentation17/02/16
MSB Half Yearly Report and Accounts (including Appendix 4D)PRICE SENSITIVE17/02/16
MSB MSB Therapy Shows Benefit In First Cohort Of RA PatientsPRICE SENSITIVE16/02/16
MSB Appendix 4C - quarterlyPRICE SENSITIVE28/01/16
MSB Change in substantial holding19/01/16
MSB CEO Presentation at JP Morgan Healthcare Conference14/01/16
MSB Phase 3 Heart Failure Trial Size Substantially ReducedPRICE SENSITIVE11/01/16
MSB Mesoblast to Present at J.P. Morgan Healthcare Conference08/01/16
MSB Mesoblast Provides Strategic Update and Q1 Financial ResultsPRICE SENSITIVE17/12/15
MSB Strategic Update and Q1 Financial Results PresentationPRICE SENSITIVE17/12/15
MSB Quarterly Results Filed on Form 6-K with SECPRICE SENSITIVE17/12/15
MSB Change of Director's Interest Notice04/12/15
MSB Change in substantial holding - J.P. Morgan (Updated)03/12/15
MSB Change in substantial holding - J.P. Morgan02/12/15
MSB Change of Director's Interest Notice30/11/15
MSB Change of Director's Interest Notice27/11/15
MSB Change in substantial holding27/11/15
MSB MSB's Japan Licensee Receives Pricing For TEMCELLPRICE SENSITIVE26/11/15
MSB Investor Update23/11/15
MSB Change of Director's Interest Notice23/11/15
MSB Change in substantial holding19/11/15
MSB Closing Of Public Offering On Nasdaq19/11/15
MSB Change in substantial holding - J.P. Morgan18/11/15
MSB Change in substantial holding17/11/15
MSB Appendix 3B16/11/15
MSB Reinstatement to Official QuotationPRICE SENSITIVE16/11/15
MSB Mesoblast Lists On NasdaqPRICE SENSITIVE16/11/15
MSB Becoming a substantial holder - J.P. Morgan05/11/15
MSB Becoming a substantial holder04/11/15
MSB MSB Files US Registration Statement, Nasdaq Listing Planned03/11/15
MSB Plan To Conduct Registered IPO In United States30/10/15
MSB Appendix 4C - quarterly30/10/15
MSB Suspension from Official QuotationPRICE SENSITIVE30/10/15
MSB Key US Patent Granted For Heart, Stroke, Vascular DiseasesPRICE SENSITIVE28/10/15
MSB Results of Meeting22/10/15
MSB CEO Presentation To 2015 Annual General Meeting22/10/15
MSB Chairman's Address to Shareholders22/10/15
MSB Celgene And Mesoblast Extend AgreementPRICE SENSITIVE16/10/15
MSB MSB Cell Therapy Shows Greatest Effect In Advanced CHFPRICE SENSITIVE30/09/15
MSB Annual Report to shareholders21/09/15
MSB Notice of Annual General Meeting/Proxy Form21/09/15
MSB Appendix 4G And Corporate Governance Statement21/09/15
MSB Full Japanese Approval For MSC ProductPRICE SENSITIVE18/09/15
MSB Appendix 3B11/09/15
MSB MSB Partner JCR Receives Recommendation For Japan ApprovalPRICE SENSITIVE04/09/15
MSB MSB 2015 Annual Financial Results Presentation17/08/15
MSB 2015 Financial Year Results And Update On P3 CHF Trial17/08/15
MSB Preliminary Final ReportPRICE SENSITIVE17/08/15
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/15
MSB Type 2 Diabetes Trial Results Published In Diabetes CarePRICE SENSITIVE23/07/15
MSB CHF Phase 2 Trial Results Published In Circulation ResearchPRICE SENSITIVE15/07/15
MSB Change of Director's Interest Notice13/07/15
MSB Positive Diabetic Nephropathy Trial ResultsPRICE SENSITIVE09/06/15
MSB Mesoblast Receives $5.8m From Aus Govt For R&DPRICE SENSITIVE05/06/15
MSB Appendix 3B and ASIC Form 48404/06/15
MSB Diabetic Nephropathy Results To Be Presented At ADA MeetingPRICE SENSITIVE18/05/15
MSB Reversed Arterial Dysfunction And Inflammation in RA ModelPRICE SENSITIVE12/05/15
MSB Employee share scheme buy-back completion - Appendix 3E & 3F05/05/15
MSB Employee share scheme buy-back - Appendix 3C01/05/15
MSB Appendix 3B17/04/15
MSB Appendix 4C - quarterlyPRICE SENSITIVE17/04/15
MSB Becoming a substantial holder from TOP17/04/15
MSB Celgene And Mesoblast Enter Into AgreementPRICE SENSITIVE13/04/15
MSB Positive EMA Meeting For Phase 3 Disc Repair ProgramPRICE SENSITIVE08/04/15
MSB Key Patent Allowed In Japan For Heart Diseases, StrokePRICE SENSITIVE27/03/15
MSB Change in substantial holding25/03/15
MSB Appendix 3B20/03/15
MSB Fast Track Access To Potential Japan Investment IncentivesPRICE SENSITIVE19/03/15
MSB Results Show Improved Survival in Children with GVHDPRICE SENSITIVE16/02/15
MSB Mesoblast Reports Half-Year Results12/02/15
MSB Mesoblast Half-Year Results Presentation12/02/15
MSB Half Yearly Report and AccountsPRICE SENSITIVE12/02/15
MSB Key US patent granted for treatment of degenerated discsPRICE SENSITIVE10/02/15
MSB Appendix 4C - quarterlyPRICE SENSITIVE30/01/15
MSB P3 trial initiated, positive 24 mth P2 results in back painPRICE SENSITIVE15/01/15
MSB Appendix 3B31/12/14
MSB Key Mesoblast Patent Claims Upheld in EuropePRICE SENSITIVE16/12/14
MSB Release of Shares from Voluntary Escrow04/12/14
MSB Appendix 3B26/11/14
MSB Change of Director's Interest Notice26/11/14
MSB Results of Meeting25/11/14
MSB CEO Presentation to 2014 Annual General Meeting25/11/14
MSB Chairman's Address to Shareholders25/11/14
MSB Ceasing to be a substantial holder-MSB.AX
12/05/16
MSB Change in substantial holding-MSB.AX
12/05/16
MSB Mesoblast Provides Q3 Financial Results and Corporate Update-MSB.AX
10/05/16PRICE SENSITIVE
MSB Third Quarter Results Presentation-MSB.AX
10/05/16
MSB Third Quarter Financial Results On Form 6-K-MSB.AX
10/05/16PRICE SENSITIVE
MSB Change in substantial holding-J.P.Morgan-MSB.AX
09/05/16
MSB Change in substantial holding-MSB.AX
09/05/16
MSB Appendix 4C - quarterly-MSB.AX
28/04/16PRICE SENSITIVE
MSB Appendix 3B and Prospectus for Issue of Employee Options-MSB.AX
28/04/16
MSB Release of Shares from Voluntary Escrow-MSB.AX
19/04/16
MSB Mesoblast Cells Show Disease Modifying Effects on Knee OA
01/04/16PRICE SENSITIVE
MSB Key US Patent Granted For Treatment Of Rheumatoid Arthritis
24/03/16PRICE SENSITIVE
MSB Mesoblast Technology Shows Potential In Type 1 Diabetes
17/03/16
MSB Appendix 3B
26/02/16
MSB GVHD Product Launched In Japan
24/02/16PRICE SENSITIVE
MSB Increased Survival Using MSB Cells In Children With aGVHD
22/02/16PRICE SENSITIVE
MSB Mesoblast Reports on First Half and Second Quarter Results
17/02/16
MSB Half Year Results Presentation
17/02/16
MSB Half Yearly Report and Accounts (including Appendix 4D)
17/02/16PRICE SENSITIVE
MSB MSB Therapy Shows Benefit In First Cohort Of RA Patients
16/02/16PRICE SENSITIVE
MSB Appendix 4C - quarterly
28/01/16PRICE SENSITIVE
MSB Change in substantial holding
19/01/16
MSB CEO Presentation at JP Morgan Healthcare Conference
14/01/16
MSB Phase 3 Heart Failure Trial Size Substantially Reduced
11/01/16PRICE SENSITIVE
MSB Mesoblast to Present at J.P. Morgan Healthcare Conference
08/01/16
MSB Mesoblast Provides Strategic Update and Q1 Financial Results
17/12/15PRICE SENSITIVE
MSB Strategic Update and Q1 Financial Results Presentation
17/12/15PRICE SENSITIVE
MSB Quarterly Results Filed on Form 6-K with SEC
17/12/15PRICE SENSITIVE
MSB Change of Director's Interest Notice
04/12/15
MSB Change in substantial holding - J.P. Morgan (Updated)
03/12/15
MSB Change in substantial holding - J.P. Morgan
02/12/15
MSB Change of Director's Interest Notice
30/11/15
MSB Change of Director's Interest Notice
27/11/15
MSB Change in substantial holding
27/11/15
MSB MSB's Japan Licensee Receives Pricing For TEMCELL
26/11/15PRICE SENSITIVE
MSB Investor Update
23/11/15
MSB Change of Director's Interest Notice
23/11/15
MSB Change in substantial holding
19/11/15
MSB Closing Of Public Offering On Nasdaq
19/11/15
MSB Change in substantial holding - J.P. Morgan
18/11/15
MSB Change in substantial holding
17/11/15
MSB Appendix 3B
16/11/15
MSB Reinstatement to Official Quotation
16/11/15PRICE SENSITIVE
MSB Mesoblast Lists On Nasdaq
16/11/15PRICE SENSITIVE
MSB Becoming a substantial holder - J.P. Morgan
05/11/15
MSB Becoming a substantial holder
04/11/15
MSB MSB Files US Registration Statement, Nasdaq Listing Planned
03/11/15
MSB Plan To Conduct Registered IPO In United States
30/10/15
MSB Appendix 4C - quarterly
30/10/15
MSB Suspension from Official Quotation
30/10/15PRICE SENSITIVE
MSB Key US Patent Granted For Heart, Stroke, Vascular Diseases
28/10/15PRICE SENSITIVE
MSB Results of Meeting
22/10/15
MSB CEO Presentation To 2015 Annual General Meeting
22/10/15
MSB Chairman's Address to Shareholders
22/10/15
MSB Celgene And Mesoblast Extend Agreement
16/10/15PRICE SENSITIVE
MSB MSB Cell Therapy Shows Greatest Effect In Advanced CHF
30/09/15PRICE SENSITIVE
MSB Annual Report to shareholders
21/09/15
MSB Notice of Annual General Meeting/Proxy Form
21/09/15
MSB Appendix 4G And Corporate Governance Statement
21/09/15
MSB Full Japanese Approval For MSC Product
18/09/15PRICE SENSITIVE
MSB Appendix 3B
11/09/15
MSB MSB Partner JCR Receives Recommendation For Japan Approval
04/09/15PRICE SENSITIVE
MSB MSB 2015 Annual Financial Results Presentation
17/08/15
MSB 2015 Financial Year Results And Update On P3 CHF Trial
17/08/15
MSB Preliminary Final Report
17/08/15PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/07/15PRICE SENSITIVE
MSB Type 2 Diabetes Trial Results Published In Diabetes Care
23/07/15PRICE SENSITIVE
MSB CHF Phase 2 Trial Results Published In Circulation Research
15/07/15PRICE SENSITIVE
MSB Change of Director's Interest Notice
13/07/15
MSB Positive Diabetic Nephropathy Trial Results
09/06/15PRICE SENSITIVE
MSB Mesoblast Receives $5.8m From Aus Govt For R&D
05/06/15PRICE SENSITIVE
MSB Appendix 3B and ASIC Form 484
04/06/15
MSB Diabetic Nephropathy Results To Be Presented At ADA Meeting
18/05/15PRICE SENSITIVE
MSB Reversed Arterial Dysfunction And Inflammation in RA Model
12/05/15PRICE SENSITIVE
MSB Employee share scheme buy-back completion - Appendix 3E & 3F
05/05/15
MSB Employee share scheme buy-back - Appendix 3C
01/05/15
MSB Appendix 3B
17/04/15
MSB Appendix 4C - quarterly
17/04/15PRICE SENSITIVE
MSB Becoming a substantial holder from TOP
17/04/15
MSB Celgene And Mesoblast Enter Into Agreement
13/04/15PRICE SENSITIVE
MSB Positive EMA Meeting For Phase 3 Disc Repair Program
08/04/15PRICE SENSITIVE
MSB Key Patent Allowed In Japan For Heart Diseases, Stroke
27/03/15PRICE SENSITIVE
MSB Change in substantial holding
25/03/15
MSB Appendix 3B
20/03/15
MSB Fast Track Access To Potential Japan Investment Incentives
19/03/15PRICE SENSITIVE
MSB Results Show Improved Survival in Children with GVHD
16/02/15PRICE SENSITIVE
MSB Mesoblast Reports Half-Year Results
12/02/15
MSB Mesoblast Half-Year Results Presentation
12/02/15
MSB Half Yearly Report and Accounts
12/02/15PRICE SENSITIVE
MSB Key US patent granted for treatment of degenerated discs
10/02/15PRICE SENSITIVE
MSB Appendix 4C - quarterly
30/01/15PRICE SENSITIVE
MSB P3 trial initiated, positive 24 mth P2 results in back pain
15/01/15PRICE SENSITIVE
MSB Appendix 3B
31/12/14
MSB Key Mesoblast Patent Claims Upheld in Europe
16/12/14PRICE SENSITIVE
MSB Release of Shares from Voluntary Escrow
04/12/14
MSB Appendix 3B
26/11/14
MSB Change of Director's Interest Notice
26/11/14
MSB Results of Meeting
25/11/14
MSB CEO Presentation to 2014 Annual General Meeting
25/11/14
MSB Chairman's Address to Shareholders
25/11/14
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.49 		Change
-0.090(5.71%) 		Mkt cap ! $1.113B
Open High Low Value Volume
$1.58 $1.59 $1.47 $7.056M 4.697M

Buyers (Bids)

No. Vol. Price($)
2 3999 $1.48
 

Sellers (Offers)

Price($) Vol. No.
$1.49 46134 7
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
$1.48 		  Change
-0.090 ( 5.55 %)
Open High Low Volume
$1.57 $1.57 $1.47 1111085
Last updated 15.59pm 21/11/2024 ?
MSB (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.